Skip to main content

OrthoPediatrics Corp. Reports Third Quarter 2022 Financial Results and Updates 2022 Revenue Guidance

WARSAW, Ind., Oct. 31, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today its financial results for the third quarter ended September 30, 2022.

Third Quarter 2022 and Recent Business Highlights

  • Helped over 17,000 children in the third quarter 2022, bringing total to more than 610,000 since the inception of OrthoPediatrics when combined with MD Orthopaedics ("MD Ortho") and Pega Medical
  • Generated total revenue of $35.0 million for third quarter 2022, up 39% from $25.1 million in third quarter 2021
  • Grew worldwide Trauma & Deformity revenue 42%, organic worldwide Scoliosis revenue 37%, worldwide Sports Medicine/Other revenue 8% in the third quarter 2022 compared to the third quarter 2021
  • Enhanced competitive position with the acquisition of Pega Medical in July
  • Completed follow-on public offering raising gross proceeds of $144 million dollars in August
  • Appointed supply chain operations veteran, Jimmy D. McDonald, to Board of Directors in October

“We’re pleased with our commercial and operational execution during the quarter, though in September, the pediatric orthopedic market faced additional headwinds beyond continued staffing shortages. Specifically, RSV infections acutely impacted case volumes in certain regions,” said David Bailey, President & CEO of OrthoPediatrics. “Despite these factors, our competitive position is as strong as ever. We remain confident in our ability to continue to drive sustainable revenue growth through increased adoption of our ever-expanding product portfolio.”

Third Quarter 2022 Financial Results
Total revenue for the third quarter of 2022 was $35.0 million, a 39% increase compared to $25.1 million for the same period last year. The increase in revenue in the third quarter of 2022 includes $4.4 million of revenue contribution from MD Ortho and Pega Medical. Excluding MD Ortho and Pega Medical, third quarter organic revenue growth was approximately 22% compared to the prior year period. U.S. revenue for the third quarter of 2022 was $26.5 million, a 37% increase compared to $19.4 million for the same period last year, representing 75.9% of total revenue. The increase in revenues in the third quarter of 2022 was driven primarily by organic growth across Scoliosis and Trauma and Deformity as well as the addition of MD Ortho and Pega Medical. International revenue for the third quarter of 2022 was $8.4 million, a 47% increase compared to $5.7 million for the same period last year, representing 24.1% of total revenue. Growth in the quarter was primarily driven by increased volumes, increased set sales to international stocking distributors in Scoliosis and Trauma and Deformity, as well as the addition of MD Ortho and Pega Medical.

Trauma and Deformity revenue for the third quarter of 2022 was $23.9 million, a 42% increase compared to $16.8 million for the same period last year. Revenue was driven by organic growth from external fixation, the PNP | Femur system, and cannulated screws as well as non-organic revenue from MD Ortho and Pega Medical of $4.4 million. Scoliosis revenue was $10.0 million, a 37% organic increase compared to $7.3 million for the third quarter of 2021. Scoliosis growth was driven primarily by increased sales of our RESPONSE™ fusion system and ApiFix non-fusion system as well as increased set sales to international stocking distributors. Sports Medicine/Other revenue for the third quarter of 2022 was $1.1 million, an 8% increase compared to $1.0 million for the same period last year.

Gross profit for the third quarter of 2022 was $25.9 million, a 40% increase compared to $18.6 million for the same period last year. Gross profit margin for the third quarter of 2022 increased to 74.1%, compared to 74.0% for the same period last year.

Total operating expenses for the third quarter of 2022 were $32.9 million, a 48% increase compared to $22.2 million for the same period last year.

Sales and marketing expenses increased $2.1 million, or 21%, to $11.9 million in the third quarter of 2022. The increase was driven primarily by increased sales commission expenses coupled with the addition of recent acquisitions.

General and administrative expenses increased $4.1 million, or 37%, to $15.1 million in the third quarter of 2022. The increase was driven primarily by the addition of personnel and resources to support the continued expansion of the business and an increase in legal expenses associated with recent acquisitions.

Total other income was $21.4 million for the third quarter of 2022, compared to $1.2 million for the same period last year. In the third quarter of 2022, we realized a $23.0 million fair value adjustment benefit which was driven by the decrease in forecasted revenue that was lower in comparison to the same period last year. In the third quarter of 2021, the Company reported a $1.4 million change.

Net income for the third quarter of 2022 was $18.5 million, compared to ($2.2) million net loss for the same period last year. Net income per share for the period was $0.88 per basic share and $0.87 per diluted share, compared to ($0.11) loss per basic and diluted share for the same period last year.

Adjusted EBITDA for the third quarter of 2022 was a gain of $1.9 million as compared to $0.5 million for the third quarter of 2021.

As of September 30, 2022, cash, short-term investments and restricted cash were $121.6 million compared to $52.5 million as of June 30, 2022, with no balance outstanding under the $50.0 million line of credit.

Full Year 2022 Financial Guidance
For full year 2022, the Company now expects its full year revenue to be in the range of $124 million to $125 million, updated from its previous guidance range of $127 million to $130 million, representing growth of 26% to 27% over 2021 revenue. The Company now expects its full year revenue, excluding recent acquisitions, to be in the range of $113 million to $114 million, representing growth of 15% to 16% over 2021 revenue. The guidance assumes roughly $11 million of combined revenue contribution from MD Ortho and Pega Medical. The Company also updated its annual set deployment to be in a range of $20 million to $24 million and continues to expect to generate several million dollars of adjusted EBITDA for full year 2022.

Conference Call

OrthoPediatrics will host a conference call on Tuesday, November 1, 2022, at 8:00 a.m. ET to discuss the results. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.orthopediatrics.com, on the Investors page in the Events & Presentations section. The webcast will be available for replay for at least 90 days after the event.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of U.S. federal securities laws. You can identify forward-looking statements by the use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "believe," "estimate," "project," "target," "predict," "intend," "future," "goals," "potential,” "objective," "would" and other similar expressions. Forward-looking statements involve risks and uncertainties, many of which are beyond OrthoPediatrics’ control. Important factors could cause actual results to differ materially from those in the forward-looking statements, including, among others: the risks related to COVID-19, the impact such pandemic may have on the demand for our products, and our ability to respond to the related challenges; and the risks, uncertainties and factors set forth under "Risk Factors" in OrthoPediatrics’ Annual Report on Form 10-K filed with the SEC on March 3, 2022, as updated and supplemented by our other SEC reports filed from time to time. Forward-looking statements speak only as of the date they are made. OrthoPediatrics assumes no obligation to update forward-looking statements to reflect actual results, subsequent events, or circumstances or other changes affecting such statements except to the extent required by applicable securities laws.

Use of Non-GAAP Financial Measures

This press release includes certain non-GAAP financial measures such as organic revenue, adjusted diluted earnings (loss) per share and Adjusted EBITDA, which differ from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”).  Sales on an organic basis excludes from our reported net revenue growth the impacts of revenue from any acquired business that have been owned for less than one year. We believe that providing the non-GAAP organic revenue is useful as a way to measure and evaluate our underlying performance consistently across the periods presented. Adjusted earnings (loss) per share in this press release represents diluted earnings (loss) per share on a GAAP basis, plus the accreted interest attributable to acquisition installment payables, the fair value adjustment of contingent consideration, trademark impairment, acquisition related costs, non-recurring professional fees, accrued legal settlement costs and minimum purchase commitment costs. The fair value adjustment of contingent consideration is associated with our estimates of the value of earn-outs in connection with certain acquisitions and the non-recurring professional fees are related to our response to a previously disclosed SEC review. We believe that providing the non-GAAP diluted earnings (loss) per share excluding these expenses, as well as the GAAP measures, assists our investors because such expenses are not reflective of our ongoing operating results. Adjusted EBITDA in this release represents net loss, plus interest expense, net plus other expense, provision for income taxes (benefit), depreciation and amortization, trademark impairment, stock-based compensation expense, fair value adjustment of contingent consideration, acquisition related costs, nonrecurring professional fees, accrued legal settlements costs, and the cost of minimum purchase commitments. The Company believes the non-GAAP measures provided in this earnings release enable it to further and more consistently analyze the period-to-period financial performance of its core business operating performance. Management uses these metrics as a measure of the Company’s operating performance and for planning purposes, including financial projections. The Company believes these measures are useful to investors as supplemental information because they are frequently used by analysts, investors and other interested parties to evaluate companies in its industry. Adjusted EBITDA is a non-GAAP financial measure and should not be considered as an alternative to, or superior to, net income or loss as a measure of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP, and it should not be construed to imply that the Company’s future results will be unaffected by unusual or non-recurring items. In addition, the measure is not intended to be a measure of free cash flow for management’s discretionary use, as it does not reflect certain cash requirements such as debt service requirements, capital expenditures and other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs and other potential cash requirements. In evaluating these non-GAAP measures, you should be aware that in the future the Company may incur expenses that are the same or similar to some of the adjustments in this presentation. The Company’s presentation of non-GAAP diluted earnings (loss) per share or Adjusted EBITDA should not be construed to imply that its future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on the Company’s GAAP results in addition to using these adjusted measures on a supplemental basis. The Company’s definition of these measures is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation. The schedules below contain reconciliations of reported GAAP net revenue to non-GAAP organic revenue, GAAP diluted earnings (loss) per share to non-GAAP diluted earnings (loss) and net loss to non-GAAP Adjusted EBITDA.

About OrthoPediatrics Corp.

Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 46 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit www.orthopediatrics.com.

Investor Contact
Philip Taylor
Gilmartin Group
philip@gilmartinir.com
415-937-5406



ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In Thousands, Except Share Data)

 September 30, 2022 December 31, 2021
    
ASSETS
Current assets:   
Cash$35,423  $7,641 
Restricted cash 1,449   1,365 
Short term investments 84,710   45,902 
Accounts receivable - trade, less allowance for doubtful accounts of $608 and $347, respectively 26,184   17,942 
Inventories, net 74,041   57,569 
Prepaid expenses and other current assets 2,751   3,229 
Total current assets 224,558   133,648 
    
Property and equipment, net 36,313   28,515 
    
Other assets:   
Amortizable intangible assets, net 66,285   55,494 
Goodwill 88,044   72,349 
Other intangible assets 14,854   14,268 
Total other assets 169,183   142,111 
    
Total assets$430,054  $304,274 
    
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:   
Accounts payable - trade 10,881   9,325 
Accrued compensation and benefits 6,323   5,351 
Current portion of long-term debt with affiliate 143   137 
Current portion of acquisition installment payable 7,630   12,862 
Other current liabilities 3,769   2,040 
Total current liabilities 28,746   29,715 
    
Long-term liabilities:   
Long-term debt with affiliate, net of current portion 799   907 
Acquisition installment payment, net of current portion 7,822   14,309 
Contingent consideration 3,460   28,910 
Deferred income taxes 5,457   4,771 
Other long-term liabilities 440   293 
Total long-term liabilities 17,978   49,190 
    
Total liabilities 46,724   78,905 
    
Stockholders' equity:   
Common stock, $0.00025 par value; 50,000,000 shares authorized; 22,896,031 shares and 19,677,214 shares issued as of September 30, 2022 (unaudited) and December 31, 2021, respectively 6   5 
Additional paid-in capital 559,339   394,899 
Accumulated deficit (168,920)  (178,026)
Accumulated other comprehensive income (7,095)  8,491 
Total stockholders' equity 383,330   225,369 
    
Total liabilities and stockholders' equity$430,054  $304,274 
    
    



ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In Thousands, Except Share and Per Share Data)

 Three Months Ended September 30, Nine Months Ended September 30,
  2022   2021   2022   2021 
Net revenue$34,950  $25,079  $91,295  $73,236 
Cost of revenue 9,061   6,525   21,859   17,914 
Gross profit 25,889   18,554   69,436   55,322 
        
Operating expenses:       
Sales and marketing 11,919   9,862   34,108   29,687 
General and administrative 15,116   11,034   42,829   34,163 
Trademark impairment 3,609      3,609    
Research and development 2,206   1,302   5,980   3,935 
Total operating expenses 32,850   22,198   86,526   67,785 
        
Operating loss (6,961)  (3,644)  (17,090)  (12,463)
        
Other expenses:       
Interest expense, net 708   542   2,485   1,851 
Fair value adjustment of contingent consideration (23,010)  (1,430)  (25,450)  3,710 
Other income 945   (267)  1,668   (802)
Total other expenses (21,357)  (1,155)  (21,297)  4,759 
        
Income (loss) before income taxes$14,396  $(2,489)  4,207   (17,222)
Provision for income taxes (benefit) (4,143)  (292)  (4,899)  (890)
Net income (loss)$18,539  $(2,197) $9,106  $(16,332)
Weighted average shares outstanding       
Basic 21,150,219   19,291,374   20,703,883   19,256,128 
Diluted 21,295,323   19,291,374   20,958,503   19,256,128 
Net income (loss) per share       
Basic$0.88  $(0.11) $0.44  $(0.85)
Diluted$0.87  $(0.11) $0.43  $(0.85)



ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)(In Thousands)

 Nine Months Ended September 30,
  2022   2021 
OPERATING ACTIVITIES 
Net income (loss)$9,106  $(16,332)
Adjustments to reconcile net loss to net cash used in operating activities:   
Depreciation and amortization 9,579   7,870 
Stock-based compensation 4,978   4,170 
Trademark Impairment 3,609    
Fair value adjustment of contingent consideration (25,450)  3,710 
Acquisition installment payable 1,926   1,701 
Deferred income taxes (4,804)  (890)
Changes in certain current assets and liabilities:   
Accounts receivable - trade (5,567)  (716)
Inventories (14,812)  (3,244)
Prepaid expenses and other current assets 696   (138)
Accounts payable - trade (389)  (956)
Accrued legal settlements    (6,342)
Accrued expenses and other liabilities 1,800   (168)
Other 903   (493)
Net cash used in operating activities (18,425)  (11,828)
    
INVESTING ACTIVITIES   
Acquisition of MD Ortho, net of cash acquired (8,360)   
Acquisition of Pega, net of cash acquired (31,730)   
Sale of short-term marketable securities 45,529   4,000 
Purchases of licenses    (7,908)
Purchase of short-term marketable securities (85,029)   
Purchases of property and equipment (10,554)  (6,468)
Net cash used in investing activities (90,144)  (10,376)
    
FINANCING ACTIVITIES   
Proceeds from issuance of debt with affiliate 31,000    
Payments on debt with affiliate (31,000)   
Installment payment for ApiFix (3,234)   
Proceeds from issuance of common stock, net of issuance costs 139,282    
Proceeds from exercise of stock options 63   137 
Payments on mortgage notes (102)  (97)
Net cash provided by financing activities 136,009   40 
    
Effect of exchange rate changes on cash 426   (266)
    
NET INCREASE (DECREASE) IN CASH AND RESTRICTED CASH 27,866   (22,430)
    
Cash and restricted cash, beginning of period$9,006  $30,132 
Cash and restricted cash, end of period$36,872  $7,702 
    
    
    
SUPPLEMENTAL DISCLOSURES   
Cash paid for interest$512  $43 
Transfer of instruments from property and equipment to inventory$(193) $80 
Issuance of common shares to acquire MD Ortho$9,707  $ 
Issuance of common shares for ApiFix installment$10,410  $ 



ORTHOPEDIATRICS CORP.
NET REVENUE BY GEOGRAPHY AND PRODUCT CATEGORY
(Unaudited)
(In Thousands)

 Three Months Ended September 30, Nine Months Ended September 30,
Product sales by geographic location: 2022   2021   2022   2021 
U.S.$26,539  $19,354  $69,687   57,930 
International 8,411   5,725   21,608   15,306 
Total$34,950  $25,079  $91,295  $73,236 
        
 Three Months Ended September 30, Nine Months Ended September 30,
Product sales by category: 2022   2021   2022   2021 
Trauma and deformity$23,892  $16,817   62,976   49,302 
Scoliosis 9,979   7,266   25,383   20,874 
Sports medicine/other 1,079   996   2,936   3,060 
Total$34,950  $25,079  $91,295  $73,236 



ORTHOPEDIATRICS CORP.
RECONCILIATION OF NET REVENUE TO NON-GAAP ORGANIC REVENUE
(Unaudited)
(In Thousands)

 Three Months Ended September 30, Nine Months Ended September 30,
Product sales by geographic location: 2022   2021   2022   2021 
As reported:       
U.S.$26,539  $19,354  $69,687   57,930 
International 8,411   5,725   21,608   15,306 
Less impact from acquisitions:       
U.S. 2,275      3,620    
International 2,119      3,386    
Organic revenue:       
U.S. 24,264   19,354   66,067   57,930 
International 6,292   5,725   18,222   15,306 
Total organic revenue$30,556  $25,079  $84,289  $73,236 
        
 Three Months Ended September 30, Nine Months Ended September 30,
Product sales by category: 2022   2021   2022   2021 
As reported:       
Trauma and deformity$23,892  $16,817   62,976   49,302 
Scoliosis 9,979   7,266   25,383   20,874 
Sports medicine/other 1,079   996   2,936   3,060 
Less: impact from acquisitions       
Trauma and deformity 4,394      7,006    
Scoliosis           
Sports medicine/other           
Organic revenue:       
Trauma and deformity 19,498   16,817   55,970   49,302 
Scoliosis 9,979   7,266   25,383   20,874 
Sports medicine/other 1,079   996   2,936   3,060 
Total organic revenue$30,556  $25,079  $84,289  $73,236 



ORTHOPEDIATRICS CORP.
RECONCILIATION OF NET LOSS TO NON-GAAP ADJUSTED EBITDA
(Unaudited)
(In Thousands)

 Three Months Ended September 30, Nine Months Ended September 30,
  2022   2021   2022   2021 
Net income (loss)$18,539  $(2,197) $9,106  $(16,332)
Interest expense, net 708   542   2,485   1,851 
Other income 945   (267)  1,668   (802)
Provision for income taxes (benefit) (4,143)  (292)  (4,899)  (890)
Depreciation and amortization 3,287   2,723   9,579   7,870 
Trademark impairment 3,609      3,609    
Stock-based compensation 1,813   1,440   5,109   4,170 
Fair value adjustment of contingent consideration (23,010)  (1,430)  (25,450)  3,710 
Acquisition related costs 54      818    
Nonrecurring professional fees          658 
Accrued legal settlements costs          150 
Minimum purchase commitment cost 101      442    
Adjusted EBITDA$1,903  $519  $2,467  $385 



ORTHOPEDIATRICS CORP.
RECONCILIATION OF DILUTED EARNINGS (LOSS) PER SHARE TO NON-GAAP ADJUSTED DILUTED EARNINGS (LOSS) PER SHARE
(Unaudited)

 Three Months Ended September 30, Nine Months Ended September 30,
  2022   2021   2022   2021 
Earnings (loss) per share, diluted (GAAP)$0.87  $(0.11) $0.43  $(0.85)
Accretion of interest attributable to acquisition installment payable 0.02   0.03   0.09   0.09 
Fair value adjustment of contingent consideration (1.12)  (0.07)  (1.24)  0.19 
Trademark impairment 0.18      0.18    
Acquisition related costs       0.04    
Nonrecurring professional fees          0.03 
Accrued legal settlements costs          0.01 
Minimum purchase commitment cost       0.02    
Earnings (loss) per share, diluted (non-GAAP)$(0.05) $(0.15) $(0.48) $(0.53)

 


Primary Logo

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.